Neuroendocrine neoplasm

This early-phase trial is testing an experimental therapy called DLL3-SAVVYZ-IL18 CAR T cells in people with advanced neuroendocrine cancers, including small cell lung cancer. The treatment involves reprogramming a patient's own immune cells to recognize and attack cancer cells t…

This phase 2 trial is testing whether adjusting the dose of the drug belinostat based on a person's genetics can make treatment safer and more effective for high-grade neuroendocrine carcinoma. About 60 adults will receive belinostat along with two other chemotherapy drugs, cispl…

This early-stage trial tests a radioactive drug (Lu-177 edotreotide) in children aged 2 to 17 with cancers that have a specific marker (SSTR-positive). The goal is to find the right dose and check safety. About 20 children whose cancer has returned or not responded to prior treat…

This study compares two schedules of the radioactive drug Lu177-Dotatate in 166 people with slow-growing midgut neuroendocrine tumors. One group gets the drug every 8 weeks (standard), the other every 16 weeks. The goal is to see if the less frequent schedule causes fewer blood-r…

This phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…

This early-phase trial tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific protein on their surface. The drug delivers a powerful radioactive particle directly to cancer cells. The study aims to find the safe…

This Phase 3 trial tests whether adding obrixtamig to standard chemotherapy helps people with advanced extrapulmonary neuroendocrine cancer live longer. About 390 adults will be randomly assigned to get either the combo or chemo alone. Obrixtamig is designed to help the immune sy…

Neuroendocrine tumors often keep growing despite treatment with somatostatin analogues, drugs that slow tumor growth and reduce hormone production. When that happens, doctors add peptide receptor radionuclide therapy (PRRT), a targeted radiotherapy, but they do not know whether c…

This study compares a new drug, zanzalintinib, to the current standard drug everolimus in people with advanced neuroendocrine tumors that have already been treated. The goal is to see which drug better slows tumor growth. About 440 participants will be randomly assigned to one of…

This study tests whether combining Lutathera (a radioactive drug given by IV) with Olaparib (a pill) can shrink neuroendocrine tumors in the pancreas or intestine that cannot be removed by surgery. About 56 adults will receive the treatment over several cycles. The goal is to fin…

This study looks at how well the drug cabozantinib works and how safe it is for adults with neuroendocrine tumors (NETs) that have continued to grow after at least one prior treatment. About 150 participants in Germany and Austria will be followed during their routine care. Docto…

This phase 2 trial tests a radioactive drug called Lu-177-DOTATATE in 130 adults with rare adrenal or neck tumors that cannot be surgically removed. The drug is given four times over about 8 months, and researchers track how long the cancer stays under control. The goal is to see…

This phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…

This study is testing a treatment called BSJ019T in Japanese patients with liver cancer that cannot be removed by surgery and has not responded to standard treatments. The goal is to see if the treatment can control the cancer's growth and how safe it is. About 51 participants wi…

This study tests a new medicine called ersodetug for people whose tumors cause dangerously low blood sugar that standard treatments can't control. About 16 adults with insulin-producing tumors will receive the drug alongside their usual care. The main goal is to see if ersodetug …

This study tests a new drug called CRN09682 in people with progressive metastatic neuroendocrine neoplasms and other solid tumors that have a specific marker (SST2). The trial has two phases: first, finding the safest dose, then testing that dose in more patients. About 150 parti…

This Phase II trial is testing whether a different dosing schedule of the drug cabozantinib can reduce side effects while still controlling cancer growth. It includes people with advanced kidney cancer (clear cell or non-clear cell) and neuroendocrine tumors (including carcinoid)…

This trial is testing whether a combination of three drugs—surufatinib, temozolomide, and S-1—can shrink or control advanced neuroendocrine tumors that have not been treated before. The study includes adults aged 18 to 75 with a specific type of tumor (MGMT0/1+). Researchers will…

This phase 2 trial tests BI 764532 (obrixtamig), an antibody-like drug designed to help the immune system attack cancer cells. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to prior treatments. The study compares two…

This study tests a radioactive drug called Lutetium-177 oxodotreotide in 74 people with advanced neuroendocrine tumors that have spread and are growing despite other treatments. The drug is designed to seek out and deliver radiation directly to tumor cells. Researchers are checki…

This study tests whether adding tivozanib (a drug that targets blood vessel growth) to atezolizumab (an immunotherapy) can help the immune system attack cancers that normally resist immunotherapy. The trial includes people with several cancer types like bile duct, pancreatic, pro…

This early-stage trial is testing a new cell therapy called NEUK203-13 for people with advanced small cell lung cancer or other neuroendocrine tumors that have not responded to standard treatments. The therapy uses immune cells (NK cells) made from stem cells and engineered to ta…

This early-phase trial tests a new drug called ADCT-701 in adults with rare cancers like neuroendocrine tumors, adrenal cancer, and malignant peripheral nerve sheath tumors. The goal is to find the safest dose and see if it can shrink tumors or slow disease. Participants receive …

This study is for people with intestinal neuroendocrine tumors that have started growing again after initial treatment with Lutathera. It compares giving two more cycles of Lutathera versus simply monitoring the tumor over six months. The goal is to see if extra treatment can bet…

This phase 2 trial tests a combination of two chemotherapy drugs (capecitabine and temozolomide) plus tiny radioactive beads delivered directly to the liver (Y90 radioembolization) in 70 people with grade 2 or 3 neuroendocrine tumors that have spread to the liver. The goal is to …

This study is testing a combination of two drugs—a targeted radioactive drug (177Lu-DOTATATE) and a PARP inhibitor (olaparib)—in children and teens aged 3 to 18 with certain solid tumors that have come back or not responded to treatment. The goal is to see if the combination is s…

This study tests a new drug called repotrectinib in people with advanced solid tumors that have certain gene changes (ALK, ROS1, or NTRK). The trial has two parts: first, finding a safe dose, and second, seeing how well the drug shrinks tumors. About 500 adults with advanced canc…

This study tests a new drug called [212Pb]VMT-α-NET, which delivers a powerful type of radiation (alpha particles) directly to tumor cells that have a specific marker (SSTR2). The trial includes 300 adults with advanced neuroendocrine tumors or meningioma that cannot be removed b…

This Phase 3 trial tests whether a radioactive drug called 177Lu-edotreotide works better than the standard drug everolimus for people with advanced neuroendocrine tumors of the lung or thymus. About 170 participants will receive either six cycles of the radioactive therapy or da…

This early-phase trial tests a cancer-killing virus (SVV-001) injected directly into tumors, combined with two immunotherapy drugs (nivolumab and ipilimumab), in 36 adults with advanced neuroendocrine tumors that have worsened after standard treatment. The main goals are to find …

This early-phase trial tests a drug called tirapazamine, which becomes active only in low-oxygen (hypoxic) areas of tumors, combined with a standard procedure that blocks blood flow to the tumor (transarterial embolization). The goal is to find the best dose and see if the combin…

This study tests a procedure called EUS-RFA, which uses a thin tube with a camera and a tiny heat probe to destroy pancreatic cysts and small tumors. It is for people who cannot have surgery or choose not to. The goal is to shrink or eliminate these growths, reduce the need for f…

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…

This study tests a combination of two drugs—cabozantinib (a daily pill) and lanreotide (a monthly injection)—in people with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have stopped responding to prior treatments. The trial has two phases: the first finds…

This study tests a new drug called RYZ101 in people with advanced neuroendocrine tumors (GEP-NETs) that have grown after prior radiation therapy. The trial has two parts: first finding the right dose, then comparing RYZ101 to standard treatments like everolimus or sunitinib. Abou…

This study is tracking 50 adults with neuroendocrine tumors who are receiving peptide receptor radionuclide therapy (PRRT). Researchers are collecting data on patient characteristics, treatment responses, survival, and side effects. The goal is to better understand who benefits f…

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack cancer, and give them back after a short course of chemotherapy. T…

This study tests a combination of two drugs, lenvatinib and pembrolizumab, in people with a rare and aggressive type of neuroendocrine tumor called well-differentiated grade 3 (WD G3). The goal is to see if the treatment can shrink tumors or stop them from growing. About 29 adult…

This phase 2 trial is testing a new radioactive drug called Terbium-161 DOTATATE in 20 people with advanced neuroendocrine tumors that have spread and stopped responding to standard treatment. The drug delivers radiation directly to cancer cells, aiming to control the disease wit…

This study tests a new treatment called CHM-2101 for people with advanced gastrointestinal cancers (stomach, colon, rectal, or neuroendocrine tumors) that have stopped responding to standard therapies. The treatment uses the patient's own immune cells, which are modified in a lab…

This early-phase trial tests a new drug called Sapu003, given with or without exemestane, in adults with advanced cancers that respond to mTOR pathways—including certain breast, kidney, liver, and neuroendocrine tumors. The main goal is to find the safest dose and check for side …

This study tests a combination of two experimental drugs, ZGGS18 and ZG005, in people with advanced solid tumors (cervical, liver, neuroendocrine, or lung cancer) that no longer respond to standard treatments. The main goals are to check safety, find the best dose, and see if the…

This trial tests whether giving three treatments together—two medicines and a surgical patch—can lower the risk of major complications after Whipple surgery for pancreatic cancer and other tumors. The study includes 400 high-risk patients with a small pancreatic duct. If successf…

This study tests a new treatment called GO306, a modified virus designed to infect and destroy cancer cells. It is for adults with advanced solid tumors (like breast, colon, or kidney cancer) that have not responded to standard therapies. The main goal is to check the safety of t…

This study is testing an oral drug called surufatinib in 350 adults with advanced neuroendocrine tumors (NETs). The drug works by cutting off blood supply to tumors and boosting the immune system. Researchers want to see if it helps control the disease and improves survival in re…

This phase 2 trial tests whether the drug zanzalintinib, taken as a maintenance therapy after initial chemotherapy, can help delay cancer progression in people with high-grade neuroendocrine neoplasms. About 32 participants will receive the drug and be monitored for how long thei…

This early-phase trial tests a new drug called MT-4561 in about 27 people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have no standard options left. The main goals are to find a safe dose and see if the drug can shrink tumors. It is a first-in-human s…

This program provides an investigational drug, ersodetug, to people with dangerously low blood sugar caused by certain tumors. It is for those who cannot join a formal clinical trial. The goal is to help control blood sugar levels when standard treatments are not enough.

This early-phase trial tests whether a drug called ASTX727 can help a radiation therapy called Lutathera work better for people with metastatic neuroendocrine tumors. The idea is that ASTX727 may turn back on a receptor on tumor cells that Lutathera needs to target. About 27 part…

This Phase 3 trial tests whether adding chemotherapy (capecitabine and temozolomide) to standard radiation therapy (PRRT) helps people with advanced neuroendocrine tumors of the stomach, pancreas, or intestines that show high activity on FDG PET scans. The study plans to enroll 1…

This early-stage trial tests a new drug called NN3201 in people with advanced cancers that have a specific marker called c-Kit. The drug is designed to deliver a chemotherapy agent directly to cancer cells, potentially killing them while sparing healthy tissue. The study will enr…

This early-phase study tests a new drug called BL-M14D1 in 22 adults with advanced small cell lung cancer, neuroendocrine tumors, or other solid cancers that have not responded to standard treatments. The drug is given by IV every 3 weeks. The main goals are to check safety, find…

This phase 3 trial tests whether personalizing the schedule of a radioactive drug (177Lu-DOTATOC) improves outcomes for people with advanced neuroendocrine tumors. About 300 participants will receive either a standard or personalized treatment plan, with some also taking capecita…

This early-phase trial is testing a radioactive tracer called FAPI-04 to see how well it lights up high-grade neuroendocrine tumors on PET/CT scans. The study will enroll 30 adults with these aggressive tumors to measure where the tracer goes in the body and how much it accumulat…

This study looks at whether a blood test for a protein called hPG80 can help find neuroendocrine tumors (NETs) earlier in people with MEN1, a genetic condition that raises tumor risk. About 297 participants with MEN1 will give blood samples, which will be compared to standard ima…

This pilot study is testing a new radioactive tracer called 89Zr-TLX250, which targets a protein (CAIX) found on certain tumor cells. The goal is to see if PET-CT scans using this tracer can detect more tumor lesions in people with liver cancer, bile duct cancer, or neuroendocrin…

This study tests a new radioactive imaging agent called 68Ga-HA-DOTATATE to see if it can safely and accurately detect neuroendocrine tumors using PET/CT scans. About 600 people with known or suspected tumors will receive the agent and be followed for one year. The goal is to imp…

This study tests a new PET imaging method that uses much less radiation to find neuroendocrine tumors. About 200 healthy volunteers and people with these tumors will get an injection of a radioactive tracer and be scanned on a high-sensitivity PET machine. The goal is to see if t…

This study is testing an artificial intelligence model called Cyst-AI that uses endoscopic ultrasound images and patient data to help doctors tell apart different types of pancreatic cysts. The goal is to improve diagnosis and guide treatment decisions. Researchers plan to enroll…

This phase 3 study is testing an improved PET/CT imaging method using a radioactive tracer called 18F-DOPA. Researchers want to see if it can better detect small lesions and reduce image artifacts in patients with conditions like congenital hyperinsulinism, neuroblastoma, neuroen…

This early study tests a special PET/CT scan that uses a modified tryptophan molecule to make tumors light up more clearly than normal tissue. About 24 adults with brain, breast, neuroendocrine, or rectal cancers will get one scan to see if this method helps doctors tell tumors a…

This Phase 3 trial tests whether the experimental drug paltusotine can reduce flushing and diarrhea in adults with carcinoid syndrome caused by neuroendocrine tumors. About 141 participants will receive either paltusotine or a placebo daily for 12 weeks. The study measures how mu…

This phase 2 trial tests whether guarana, a natural supplement from the Amazon, can reduce fatigue in 86 people with neuroendocrine tumors or gynecologic cancers. Participants take either guarana or a placebo daily for up to 42 days, and researchers measure changes in fatigue usi…

This study tests whether using virtual reality (VR) can reduce severe belly pain and improve quality of life in people with digestive tract cancers. 360 participants will be split into three groups: one using a skills-based VR program, one using distracting VR videos, and a contr…

This study is for Black adults newly diagnosed with gastrointestinal cancer. It focuses on ensuring patients receive proper biomarker testing and evidence-based care, helping them find and join clinical trials if they choose, and providing easy-to-understand information about the…

This study is creating a large database of medical information and blood samples from 350 adults receiving metabolic radiotherapy for thyroid, prostate, or neuroendocrine cancers. The goal is to provide researchers with valuable data to better understand these treatments. No new …

Researchers at IRCCS San Raffaele are creating a registry of images and videos from endoscopic ultrasound procedures performed to investigate pancreatic diseases. The study will gather data from about 12,000 patients with conditions like pancreatitis, pancreatic cancer, and neuro…

This study collects extra blood, urine, and tumor samples from children and adults with certain cancers to build a large tissue repository. Researchers will analyze these samples to learn more about the genetic and molecular makeup of these tumors. The goal is to support future s…

This study is a large registry that collects health information and leftover tumor or blood samples from up to 75,000 children and young adults with cancer. The goal is to track outcomes and gather data to help doctors find better ways to treat and care for these patients over ti…

This study uses a special PET scan to see how the experimental drug BI 764532 travels through the body and reaches tumors. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers who have run out of standard treatment options. The main goal is to mea…

This study looks at whether measuring the amount of certain targeted cancer drugs in the blood can help find the best dose for each patient. It involves adults with advanced digestive cancers like colorectal, liver, and stomach tumors who are already taking these medications. By …

This study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…

This study adds a heart-focused PET scan to a standard cancer imaging test (Gallium-68-DOTATOC) in 99 adults with neuroendocrine tumors. The goal is to see if the scan can detect heart inflammation linked to age and cardiovascular risk factors. Researchers will also compare scan …

This study looks at whether special breathing exercises can help the brains of people with multiple sclerosis or cancer, as well as their caregivers. Researchers will use MRI scans to see how breathing affects oxygen flow in the brain. The goal is to understand the connection bet…

This study follows people with von Hippel-Lindau (VHL) disease who have pancreatic tumors or cysts. The goal is to learn how these growths change over time and to see if a special type of scan (68-Gallium DOTATATE PET/CT) can find them better. Participants will have regular check…

This study looks at whether follow-up care for people with rare tumors can be done just as well by a nurse remotely as by a doctor in person. About 88 adults recently diagnosed with a rare tumor will be randomly assigned to either in-person doctor visits or remote nurse check-ins…

This study looks at people with small intestinal neuroendocrine tumors that have spread and cannot be cured. It compares those who had surgery to remove the main tumor plus other treatments against those who had only other treatments. The goal is to see if surgery helps patients …

This study is for people with neuroendocrine tumors who are about to receive or have already received peptide receptor radionuclide therapy (PRRT). Researchers want to find out if certain genetic changes in the blood can predict who might later develop myelodysplastic syndrome (M…

This study looks at whether having a pharmacist review all medications (including those from other doctors) can improve safety for cancer patients receiving targeted radionuclide therapy. The study will include 600 adults with thyroid cancer, metastatic prostate cancer, or neuroe…

This study looks at whether repeated doses of a gadolinium-based contrast agent (a dye used in MRI scans) affect motor and cognitive functions in healthy adults. About 2076 participants will receive annual imaging and undergo tests over 5 years. The goal is to compare changes in …

This study looks at how factors like age, sex, tumor grade, and location influence how well treatments work for people with well-differentiated gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Researchers will follow 450 patients to see how long their disease stays und…

This study is testing whether a special type of ultrasound (called D-CEUS) can predict if a targeted radiation therapy (PRRT) is working in people with advanced neuroendocrine tumors of the pancreas or gut. About 30 adults with these tumors will get D-CEUS scans before, during, a…

This study at Strasbourg University Hospital will check the nutritional status of 100 adults with gastroenteropancreatic neuroendocrine tumors. Researchers want to see if malnutrition is linked to worse outcomes. The goal is to understand whether improving nutrition could help pa…

This study aims to collect tissue samples and health information from 300 adults with neuroendocrine neoplasms (NENs), including adrenocortical carcinoma. Researchers will follow participants over time to understand how these rare cancers grow and respond to treatments. The goal …

This study is testing whether an artificial intelligence (AI) tool can help match cancer patients with the right clinical trials. Researchers will enroll up to 50,000 people with various cancers to see if the AI improves trial enrollment rates and patient outcomes. The goal is to…

This study collects and stores tissue and blood samples from people with stomach, esophageal, pancreatic, liver, and other gastrointestinal cancers. The goal is to build a large database of samples and medical information to help researchers understand these cancers better. Parti…